MaaT Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	4.52	3.22	2.23	1.43	0.97
Revenue	4.52	3.22	2.23	1.43	0.97
Revenue Growth (YoY)	40.67%	44.34%	55.80%	47.12%	-
Cost of Revenue	-	1.61	0.88	0.64	0.33
Gross Profit	4.52	1.6	1.35	0.79	0.64
Selling, General & Admin	8.22	6.88	5.38	4.43	2.92
Research & Development	29.05	26.88	20.49	13.98	8.96
Other Operating Expenses	-4.42	-3.72	-4.58	-4.06	-2.34
Operating Expenses	32.85	30.03	21.29	14.34	9.54
Operating Income	-28.33	-28.43	-19.94	-13.56	-8.89
Interest Expense	-1.56	-0.87	-0.4	-0.19	-0.12
Interest & Investment Income	-	-	-	0.05	-
Other Non Operating Income (Expenses)	-1.17	0.39	0.63	-0.02	-0.01
Pretax Income	-31.06	-28.9	-19.72	-13.71	-9.02
Net Income	-31.06	-28.9	-19.72	-13.71	-9.02
Net Income to Common	-31.06	-28.9	-19.72	-13.71	-9.02
Shares Outstanding (Basic)	-	13	11	10	2
Shares Outstanding (Diluted)	-	13	11	10	2
Shares Change (YoY)	-	14.95%	14.89%	307.65%	135.06%
EPS (Basic)	-	-2.21	-1.73	-1.39	-3.72
EPS (Diluted)	-	-2.21	-1.73	-1.39	-3.72
Free Cash Flow	-	-22.79	-19.76	-13.27	-8.17
Free Cash Flow Per Share	-	-1.75	-1.74	-1.34	-3.37
Gross Margin	100.00%	49.81%	60.59%	55.11%	66.05%
Operating Margin	-626.19%	-883.95%	-895.11%	-947.97%	-914.92%
Profit Margin	-686.58%	-898.76%	-884.96%	-958.95%	-927.88%
Free Cash Flow Margin	-	-708.77%	-887.03%	-927.76%	-840.23%
EBITDA	-28.1	-28.2	-19.74	-13.32	-8.71
D&A For EBITDA	0.23	0.23	0.2	0.24	0.18
EBIT	-28.33	-28.43	-19.94	-13.56	-8.89
Advertising Expenses	-	0.25	0.24	0.19	0.15

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.